Image

NOPE37: Angiogenic Factors for Managing Term Preeclampsia

NOPE37: Angiogenic Factors for Managing Term Preeclampsia

Recruiting
18 years and older
Female
Phase N/A

Powered by AI

Overview

This study tests the hypothesis that, in women with preeclampsia without severe features, delivery management based on sFlt-1/PlGF would reduce the rate of induction of labor without worsening the rate of progression to preeclampsia with severe features and other maternal complications.

Description

Participants with preeclampsia without severe features between 36 and 38+6 weeks, who do not meet any exclusion criteria, will be randomly assigned to two groups:

  • In the study group, if angiogenic factors are normal (sFlt-1/PlGF \<38), delivery will be delayed until 39 weeks; if any other medical condition is present, delivery will be scheduled according to the specific protocol for it.
  • In the study group, if angiogenic factors are abnormal (sFlt-1/PlGF ≥38), labor will be induced at ≥37 weeks.
  • In the control group, labor will be recommended at 37 weeks, as is currently standard.
  • In both groups, NT-proBNP levels will be measured at enrollment.
  • In both groups, a satisfaction questionnaire will be completed at enrollment and 4 weeks after delivery.
  • In both groups, if any of the following is present, delivery will be recommended immediately (within 24 hours):
    1. preeclampsia with severe features according to ACOG criteria
    2. decreased fetal movements
    3. absent or reversed diastolic flow in the umbilical artery
    4. non-reassuring CTG
    5. biophysical profile score ≤6
    6. oligohydramnios (largest vertical pocket \<2 cm)

Eligibility

Inclusion Criteria:

  • Age ≥18 years
  • Singleton pregnancy
  • Preeclampsia without severe features according to the ACOG definition
  • Antegrade diastolic flow in the umbilical artery Doppler
  • Gestational age between 36+0 and 38+6 weeks of gestation
  • Gestational age confirmed by fetal crown-rump length measurement in the first-trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates

Exclusion Criteria:

  • Fetal death
  • Preeclampsia with severe features according to the ACOG definition, eclampsia, or any condition that requires immediate delivery
  • Absent or reversed end-diastolic flow in the umbilical artery Doppler
  • Non-reassuring CTG
  • Decreased fetal movements
  • Biophysical profile score ≤6
  • Oligohydramnios
  • Refusal to provide informed consent
  • Fetal malformation
  • Placental abruption
  • Antiphospholipid antibody syndrome

Study details
    Preeclampsia

NCT07193680

Hospital Universitari Vall d'Hebron Research Institute

1 February 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.